118 related articles for article (PubMed ID: 29696459)
1. Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
Rolli FR; Ruggeri M; Kheiraoui F; Drago C; Basile M; Favaretti C; Cicchetti A
Eur J Health Econ; 2018 Dec; 19(9):1365-1374. PubMed ID: 29696459
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
5. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
Sperl J; Horvath G; Halota W; Ruiz-Tapiador JA; Streinu-Cercel A; Jancoriene L; Werling K; Kileng H; Koklu S; Gerstoft J; Urbanek P; Flisiak R; Leiva R; Kazenaite E; Prinzing R; Patel S; Qiu J; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Platt HL
J Hepatol; 2016 Dec; 65(6):1112-1119. PubMed ID: 27542322
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
10. Drug Pricing Evolution in Hepatitis C.
Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
[TBL] [Abstract][Full Text] [Related]
16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Cure S; Guerra I; Cammà C; Craxì A; Carosi G
J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
[TBL] [Abstract][Full Text] [Related]
18. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
[TBL] [Abstract][Full Text] [Related]
19. Elbasvir/grazoprevir, Velpatasvir/sofosbuvir, and Eteplirsen.
Hussar DA; Tidwell WP
J Am Pharm Assoc (2003); 2017; 57(1):129-132. PubMed ID: 28038699
[No Abstract] [Full Text] [Related]
20. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]